Naders proactive statement regarding enrollment in
Post# of 154020
(Total Views: 566)
Posted On: 10/29/2021 6:35:16 PM
Naders proactive statement regarding enrollment in brazil is again not satisfying.
As of today the 7day average for COVID in Sao Paulo is 59 deaths/ day. We have 6 major hospitals in Sao Paulo participating in our trial. Those 59 death patients/ day or 413 death patients/ months were once moderate and then critical patients and some or most of them must have fulfilled our trial criteria. And this is only Sao Paulo!
Howcome our trials are not filled at an acceptable rate (e.g. at 10% of the moderate and critical patients)? Do our hospitals have no moderate and critical patients? Are our trial criteria problematic? Do they have other COVID trials running in parallel and we are not priority No. 1? What's going on?
btw. our critical enrollment rate must heavily suffer from our success in the moderate trial, since we have more or less the same trial sites for both trials (e.g. in Sao Paulo). How did they consider this problem for the critical trial enrollment or do we have to wait until enrollment for moderate is over?! I assume our (placebo) moderate trial patients cannot become participants in our critical trial ...
As of today the 7day average for COVID in Sao Paulo is 59 deaths/ day. We have 6 major hospitals in Sao Paulo participating in our trial. Those 59 death patients/ day or 413 death patients/ months were once moderate and then critical patients and some or most of them must have fulfilled our trial criteria. And this is only Sao Paulo!
Howcome our trials are not filled at an acceptable rate (e.g. at 10% of the moderate and critical patients)? Do our hospitals have no moderate and critical patients? Are our trial criteria problematic? Do they have other COVID trials running in parallel and we are not priority No. 1? What's going on?
btw. our critical enrollment rate must heavily suffer from our success in the moderate trial, since we have more or less the same trial sites for both trials (e.g. in Sao Paulo). How did they consider this problem for the critical trial enrollment or do we have to wait until enrollment for moderate is over?! I assume our (placebo) moderate trial patients cannot become participants in our critical trial ...
(3)
(0)